EUVIMEDEUVIMED entdecken
Mixed-Methods-StudieOpen Access · CC BY-NC 4.0

Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative Blueprint

Meredith Y Smith, Rachel Davis, Priya Bahri, Delphine Saragoussi, Viviana Nguyen, Gita A Toyserkani, Alison Hamilton

Drug Safety · 2025

DOI: 10.1007/s40264-025-01533-w ↗

Kurz gefasst

Mixed-Methods-Studie in der Zeitschrift Drug Safety, 2025. Verfasst von Meredith Y Smith und 6 weiteren Autor:innen. Beteiligte Einrichtung: Evidera, Inc., 929 North Front Street, Wilmington, NC, 28401, USA. tantmieux57@gmail.com. Hauptthemen laut MEDLINE: Program Evaluation, Risk Evaluation and Mitigation, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Significant methodological shortcomings have been documented to date in risk minimisation program evaluations for medicinal products, including overreliance on survey methods alone. Recently updated guidances from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recommend the use of frameworks and mixed methods designs to improve the rigor of these assessments. OBJECTIVE: The purpose of this paper was to exemplify how a mixed methods approach, guided by an implementation science framework, can be used to design the evaluation of a risk minimisation program. METHODS: We selected the Practical, Robust, Implementation and Sustainability Model (PRISM) as the implementation science framework to guide our mixed methods approach. PRISM provides a comprehensive and systematic approach to measuring the key domains relevant to the implementation and outcomes of a risk minimisation program. We mapped the PRISM domains to the evaluation dimensions described in the EMA and FDA guidances. We then specified a mixed methods evaluation design and data collection methods using a fictitious risk minimisation program as a case study for illustrative purposes. RESULTS: On the basis of our case study, we developed quantitative and qualitative measures, including specific items for surveys and interviews, for both formative and summative evaluations. For both the formative and summative evaluations, measures focussed on assessing (1) contextual factors that could affect program implementation and impact and (2) outcomes including implementability and acceptability as well as degree of program reach, adoption, implementation, effectiveness and maintenance. CONCLUSIONS: Mixed methods, guided by a well-established implementation science framework, can be applied to ensure comprehensive formative and summative evaluations that provide fit-for-purpose information that may inform regulatory decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Program EvaluationRisk Evaluation and MitigationDrug-Related Side Effects and Adverse ReactionsUnited StatesEuropeHumansUnited States Food and Drug AdministrationResearch Design

Autor:innen und Institutionen

  • Evidera, Inc., 929 North Front Street, Wilmington, NC, 28401, USA. tantmieux57@gmail.com.
  • Department of Regulatory and Quality Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA. tantmieux57@gmail.com.
  • Evidera, Inc., 929 North Front Street, Wilmington, NC, 28401, USA.
  • European Medicines Agency, Amsterdam, The Netherlands.
  • Sanofi, 82, Gentilly, France.
  • Office of Medication Error Prevention and Risk Management, US Food and Drug Administration, Silver Spring, MD, USA.

Zitieren

APA

Smith, M. Y., Davis, R., Bahri, P., Saragoussi, D., Nguyen, V., Toyserkani, G. A., & Hamilton, A. (2025). Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative Blueprint. Drug Safety. https://doi.org/10.1007/s40264-025-01533-w

Vancouver

Smith MY, Davis R, Bahri P, Saragoussi D, Nguyen V, Toyserkani GA, et al. Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative Blueprint. Drug Safety. 2025. doi:10.1007/s40264-025-01533-w

BibTeX
@article{Smith2025,
  author = {Smith, Meredith Y and Davis, Rachel and Bahri, Priya and Saragoussi, Delphine and Nguyen, Viviana and Toyserkani, Gita A and Hamilton, Alison},
  title = {Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative Blueprint},
  journal = {Drug Safety},
  year = {2025},
  doi = {10.1007/s40264-025-01533-w}
}
Kostenlos starten →